Fred Alger Management 13F: Adds $110M to DNTH Stake

Fred Alger Management Boosts Position in Dianthus Therapeutics

Fred Alger Management significantly increased its investment in Dianthus Therapeutics, Inc. (NasdaqCM:DNTH), according to its latest Form 13F filing with the Securities and Exchange Commission. The institutional investor added 1,128,463 shares of the clinical-stage biotechnology company during the period, marking a 3,372.6% surge in its holdings. The fund wrapped up the reporting period with a total of 1,161,923 shares, representing a reported value of roughly $113.3 million based on filings.

Big Jump in Portfolio Holdings

The massive addition brought a dramatic shift to the fund's exposure in the biotech sector. Prior to the trade, Fred Alger Management held just 33,460 shares of Dianthus Therapeutics. By picking up more than 1.12 million shares at an estimated cost basis of $61.97, the firm turned a small holding into a multi-million dollar position. Because 13F filings look backward at holdings from the end of the reporting period, this snapshot may not reflect what the fund holds right now.

Dianthus Therapeutics Stock Valuation

Dianthus Therapeutics shares recently traded at $97.48, placing the stock well above its 200-day moving average of $79.04, though it sits below its 50-day moving average of $106.78. The company carries a market capitalization of roughly $5.40 billion. Over the past 52 weeks, the stock has moved between a low of $32.22 and a high of $117.88. The firm operates with a strong current ratio of 26.1, pointing to ample short-term liquidity to fund its ongoing drug development work.

Analysts Set New Price Targets

Wall Street firms have kept a close eye on the biotech developer, backed by a consensus recommendation of strong buy and 15 analyst opinions. On October 15, 2026, HC Wainwright & Co. reiterated its buy rating with a $158.00 price target. Earlier in the autumn, JP Morgan initiated coverage on September 11, 2026, with an overweight rating and a $135.00 price target, while Citigroup initiated coverage on September 4, 2026, with a buy rating and a $156.00 price target. Truist Securities also adjusted its outlook on August 6, 2026, lifting its price target to $128.00 from $110.00 while maintaining a buy rating. Analyst price targets across the board range from a low of $122.00 up to $200.00, with a mean target of $140.80.

Inside the Pipeline

Dianthus Therapeutics focuses on creating new treatments for patients suffering from severe autoimmune conditions. Its lead clinical candidate, claseprubart, is a monoclonal antibody engineered to target the active C1s complement protein with high potency and selectivity. The company is also advancing DNTH212, a bifunctional fusion protein designed to reduce Type 1 interferon production while simultaneously suppressing B cell function through BAFF and APRIL inhibition. Founded in 2019 and based in New York, the firm employs 92 people.

What to Watch at Dianthus Therapeutics, Inc.

Investors will look to subsequent quarterly filings to see whether Fred Alger Management keeps expanding its footprint in the biotech company or starts taking profits. The company's next financial results are scheduled for release on November 5, 2026. As always, these 13F reports reflect older portfolio adjustments and offer a retrospective look at institutional capital flows.